Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Lactobacillus reuteri Assists Engineered Bacteria That Target Tumors to Release PD‐L1nb to Mitigate the Adverse Effects of Breast Cancer Immunotherapy

Yue, Lijun, Geng, Feng, Jin, Jiayi, Li, Wenzhen, Liu, Ben, Du, Maoru, Gao, Xue, Lü, Junhong, Pan, Xiaohong · 2024 · Biotechnology Journal

Abstract

Programmed death protein‐ligand 1 (PD‐L1) inhibitors demonstrate significant antitumor efficacy by modulating T‐cell activity and inhibiting the PD‐1/PD‐L1 pathway, thus enhancing immune responses. Despite their robust effects, systemic administration of these inhibitors is linked to severe immune toxicity. To address this issue, we engineered a strain, REP, which releases PD‐L1 nanoantibodies (PD‐L1nb) to treat breast cancer and attenuate immunotherapy‐related side effects. REP selectively targets tumors and periodically releases PD‐L1nb within tumors via a quorum‐sensing lysis system. Administration of 108 colony‐forming units (CFU) of REP led to a substantial 52% reduction in tumor growth, achieved through the sustained release of PD‐L1nb. Importantly, there were no detectable lesions in other organs, with the exception of mild intestinal damage. Further, we explored the potential of a combined treatment using Lactobacillus reuteri (LR) and REP to alleviate intestinal inflammation. LR modulates the expression of inflammatory markers IL‐1β, IL‐6, and IL‐10 through the JNK pathway, reducing intestinal inflammation without compromising REP's antitumor efficacy. Consequently, we formulated a dual strategy employing an engineered strain and probiotics to reduce the adverse effects of immunotherapy in cancer treatment.

Overview

Integrity signals

Registry

Crossref · 10.1002/biot.202400428

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 45 references

Cited by

See all 15

Metadata

Authors
Yue, L., Geng, F., Jin, J., Li, W., Liu, B., Du, M., Gao, X., Lü, J., & Pan, X.
Affiliations
Binzhou Medical University (CN)
Corresponding author
  • Geng, Feng
  • Pan, Xiaohong
Venue
Biotechnology Journal
Publisher
Wiley
Published
2024-12
Volume
19
Issue
12
Pages
e202400428-e202400428
ISSN
  • 1860-6768 (ISSN-L)
  • 1860-7314
OpenAlex
W4405727760
Cited by
14
References
45
Citations by year
2026: 9 · 2025: 5
FWCI
2.64
Type
journal article
Language
en
Open access
closed
Locations
  • Biotechnology Journal (publishedVersion)
  • PubMed (publishedVersion)
Funders
Natural Science Foundation of Shandong Province (ZR2022MC121)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
Lactobacillus reuteri, engineered bacteria, breast cancer, immune checkpoint inhibitors, immunotherapy toxicity, probiotics, intestinal inflammation, JNK signaling, IL-1β, interleukin-6, IL-10, tumor growth inhibition
MeSH terms
Immune Checkpoint Inhibitors, Animals, Breast Neoplasms, Female, Humans, Immunotherapy, Mice, Inbred BALB C, Cell Line, Tumor, Mice, Limosilactobacillus reuteri, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lactobacillus reuteri Assists Engineered Bacteria That Target Tumors to Release PD‐L1nb to Mitigate the Adverse Effects of Breast Cancer Immunotherapy. https://app.cochat.ai/papers/10.1002/biot.202400428
The paper
Yue, L., Geng, F., Jin, J., Li, W., Liu, B., Du, M., Gao, X., Lü, J., & Pan, X. (2024). Lactobacillus reuteri Assists Engineered Bacteria That Target Tumors to Release PD‐L1nb to Mitigate the Adverse Effects of Breast Cancer Immunotherapy. Biotechnology Journal. https://doi.org/10.1002/biot.202400428

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.